Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

57.73
-1.9700-3.30%
Post-market: 57.890.1600+0.28%18:49 EST
Volume:820.64K
Turnover:47.58M
Market Cap:4.09B
PE:-24.20
High:59.31
Open:57.90
Low:57.02
Close:59.70
52wk High:94.90
52wk Low:13.22
Shares:70.84M
Float Shares:51.39M
Volume Ratio:1.06
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3852
EPS(LYR):-2.3276
ROE:-11.86%
ROA:-9.39%
PB:2.70
PE(LYR):-24.80

Loading ...

Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents

Reuters
·
Jan 06

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

BUZZ-Structure Therapeutics doubles while other obesity drug developers decline

Reuters
·
Dec 31, 2025

Structure Therapeutics Inc. : H.c. Wainwright Raises Target Price to $90 From $60

THOMSON REUTERS
·
Dec 19, 2025

BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data

Reuters
·
Dec 18, 2025

BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671

Reuters
·
Dec 17, 2025

Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity

Reuters
·
Dec 17, 2025

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity

THOMSON REUTERS
·
Dec 17, 2025

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Dec 17, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dow Jones
·
Dec 12, 2025

Structure Therapeutics Inc : Leerink Partners Raises Target Price to $90.00 From $44.00

THOMSON REUTERS
·
Dec 11, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

GlobeNewswire
·
Dec 11, 2025

Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly

Tiger Newspress
·
Dec 10, 2025

Structure Therapeutics Prices $650 Million Upsized Public Offering

MT Newswires Live
·
Dec 10, 2025

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

GlobeNewswire
·
Dec 10, 2025

Structure Therapeutics Plans $500 Million Public Offering

MT Newswires Live
·
Dec 09, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
Dec 09, 2025